Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

Canada NewsWire March 8, 2021

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

Canada NewsWire February 26, 2021

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

Canada NewsWire February 18, 2021

MindMed's LSD Neutralizer Study Begins

Canada NewsWire February 17, 2021

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

Canada NewsWire February 11, 2021

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

Canada NewsWire February 2, 2021

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

Canada NewsWire January 20, 2021

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Canada NewsWire January 14, 2021

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

PR Newswire January 12, 2021

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

Canada NewsWire January 7, 2021

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire January 4, 2021

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire December 21, 2020

MindMed Upsizes Previously Announced Bought Deal Public Offering

Canada NewsWire December 15, 2020

MindMed Announces $50 Million Bought Deal Public Offering

Canada NewsWire December 14, 2020

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

Canada NewsWire December 14, 2020

MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)

Canada NewsWire December 11, 2020

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire December 8, 2020

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire November 30, 2020

MindMed Upsizes Previously Announced Bought Deal Public Offering

Canada NewsWire November 25, 2020

MindMed Announces $25 Million Bought Deal Public Offering

Canada NewsWire November 25, 2020